{"id":"NCT03364309","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis","officialTitle":"A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-26","primaryCompletion":"2020-06-04","completion":"2020-06-04","firstPosted":"2017-12-06","resultsPosted":"2021-06-25","lastUpdate":"2021-06-25"},"enrollment":438,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ixekizumab 80mg Q4W","type":"EXPERIMENTAL"},{"label":"Ixekizumab 80mg Q2W","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":3.4,"sd":null},{"arm":"Ixekizumab 80mg Q4W","deltaMin":79.9,"sd":null},{"arm":"Ixekizumab 80mg Q2W","deltaMin":86.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":17,"countries":["China"]},"refs":{"pmids":["39535685","39347926"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":88},"commonTop":["Upper respiratory tract infection","Injection site reaction","Tinea pedis","Urticaria","Hepatic function abnormal"]}}